Wetherby-based life sciences company Avacta Group said it will present new preclinical data on two breakthroughs in its cancer drug treatment platform at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain from 23-25 October.

The company is currently developing its platform, which it calls ‘pre|CISION’, that can delivers cancer drugs directly to tumours while minimizing exposure to normal tissues and decreasing side effects. 

It said the first advance is the design and preclinical analysis of the company’s newest development candidate, AVA6103. The second advance is the first description of a novel class of engineered biotherapeutics, called Affirmer Drug Conjugates.